ClinicalTrials.gg
RecruitingNCT05795634Stress-ADUpdated Jan 29, 2026

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

An interventional study of Trier Social Stress Test in Mild Cognitive Impairment and Alzheimer Disease, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.

Planned enrollment
5th of 33
240 · median 52
Started
2023
with 6 others
No phase
22 of 34
8 open now
Primary completion
2028-03
later than 12 of 14 live
Registered
22nd of 34
by date

Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2023, is one of 22 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 22nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Cognitive Dysfunction by Johns Hopkins University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.

The main question[s] it aims to answer are:

  • Does the hormone response to acute stress predict the degree of cognitive impairment following acute stress?
  • Do genes associated with the risk for Alzheimer's disease influence the relationship between stress hormone response to stress and cognitive impairment following stress?
  • Do cognitive impairment following acute stress and genes associated with the risk for Alzheimer's disease predict cognitive decline and change in biomarkers for Alzheimer's disease 2 years later?

Participants will have 3 in-person study visits. The first 2 will occur at baseline and the 3rd visit will occur 2 years later. During the visits, participants will provide blood and saliva samples, undergo a 10-minute social stress procedure, complete questionnaires, and take tests of memory and other thinking skills. Someone who knows the participant (a "study partner") will be asked questions about the participant's daily functioning at the first and 3rd study visits.

Read the detailed description

In the wake of discouraging results from treatment trials in Alzheimer's disease (AD), there is emerging consensus that the lack of efficacy in these trials is attributable to heterogeneity in the course of AD. Among the potential causes of heterogeneity, the investigators aim to focus on vulnerability to acute stress. Although associations between stress and the risk of AD are well established, these findings have not been used to inform AD intervention efforts. The investigators aim to address this crucial gap. Considering that in healthy individuals, acute stress can impair cognition in those who have risk factors for AD, the investigators propose that these individuals may represent a specific endophenotype who could be targeted for AD treatment trials. The investigators' prior findings implicate the endocrine stress response as an important component of AD risk that warrants further study.

The investigators aim to conduct a prospective study to examine the associations among the acute endocrine stress response, cognitive impairment following acute stress, and subsequent cognitive decline. For the investigators' basic study design, the investigators will induce acute stress with the Trier Social Stress Test (TSST; 5 minutes of public speaking and 5 minutes of mental arithmetic) and then administer a battery of cognitive tests. Two cognitive domains-memory and executive functioning-will be the primary cognitive outcomes. Salivary samples collected at fixed intervals will be used to measure stress hormone response; cortisol will the primary endocrine hormone outcome. The investigators will also examine the influence of apolipoprotein E (APOE) gene polymorphisms and polygenic risk scores, conduct sex-stratified analyses, and collect blood-based biomarkers for AD.

The investigators' study has 3 primary aims:

  1. To determine the association between endocrine response to acute stress and memory and executive test performance following acute stress in individuals with MCI due to AD.
  2. To examine the moderating effect of APOE genotype and polygenic risk score derived from genome wide genotyping on the association between endocrine response to acute stress and cognitive test performance following acute stress in individuals with MCI due to AD.
  3. To determine predictors of cognitive decline and neurodegeneration at 2-year follow-up.

Secondary Aims: Conduct the analyses from Specific Aims 1-3 in men and women separately in order to identify sex-specific predictors of stress-induced memory and executive impairment and cognitive decline after 2 years. As an exploratory aim, the investigators will examine the influence of personality factors and stressful life events on the hypothesized associations.

For this study, participants will come to the clinic for 3 study visits. For the first visit, participants will be asked to bring someone who knows the participant well (a "study partner"). During that visit, participants and the participants' study partners will answer questions about the participant's daily functioning. In addition, participants (but not the participants study partners) will take paper-and-pencil tests and provide a blood sample. About one month later, participants will return for a second study visit, but the participants' study partner does not need to come to that visit. During that second visit, participants will undergo a brief procedure (public speaking and mental math) that is designed to cause stress, during which the investigators will measure participants' stress hormones by asking participants to provide the investigators with samples of the participants' saliva. Two years later, participants and the participants' study partners will return for Visit 3. At that visit, the investigators will ask participants to provide another blood sample and complete tests of memory and other thinking skills. Study partners will answer questions about the participants during this visit but will not take any tests or provide a blood sample.

03

Conditions studied

  • Mild Cognitive Impairment
  • Alzheimer Disease

Keywords

  • Stress
  • Neuropsychology
  • Endocrine
  • Genetics
  • Blood biomarkers
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Subjects with Mild Cognitive Impairment (MCI)

  • Age 60 and older
  • Fluent English speaker
  • Able to provide for study procedures
  • Willing and able to return for 2-year-followup visit
  • Willing and able to provide an informant who can participate in the screening and 2-year study visits
  • >17 and \<30
  • Meets clinical and cognitive criteria for mild cognitive impairment (MCI) using National Institute on Aging (NIA)/Alzheimer's Association 2011 criteria (see below)

Exclusion Criteria for Subjects with MCI

  • Current smoker
  • Current or past history of major psychiatric illness, including schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder
  • Neurological disorder, including Parkinson's disease, Huntington's disease
  • Current or past history of immune disorder, including multiple sclerosis
  • Current or past history of drug dependence
  • Treatment within the last six months with: neuroleptics, sedative hypnotics, or
  • History of head injury with loss of consciousness for more than ½ hour, stroke, or seizure
  • General surgery within the last 3 months
  • Sensory impairment (poor vision or hearing) significant enough to interfere with ability to provide valid cognitive test data

Clinical and Cognitive Criteria for MCI due to AD

  • Cognitive concern reflecting a change in cognition reported by patient or informant or clinician (i.e., historical or observed evidence of decline over time)
  • Objective evidence of impairment in one or more cognitive domains, typically including memory (i.e., formal or bedside testing to establish level of cognitive function in multiple domains)
  • Preservation of independence in functional abilities
  • Not demented
  • Etiology of MCI consistent with AD pathophysiological process

Inclusion Criteria for Study Partners

  • Age 21 or older
  • Able to participate in an interview
  • Willing and able to attend study visits
  • Willing and able to return for 2-year-followup visit

Exclusion Criteria for Study Partners

  • Unwilling to answer questions about the participant with MCI
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Other
    Trier Social Stress Test

    All participants in the study will get undergo the same stress procedure

    Behavioral: Trier Social Stress Test

Interventions

  • BehavioralTrier Social Stress Test

    Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic

06

What researchers measure

Primary outcomes

  1. Change in mean memory test composite score

    Change in the mean composite score of the following memory tests: Neuropsychological Assessment Battery Word List Memory test, Morris Revision test, and a computerized Pattern Separation Task, with higher composite score indicating better memory

    Time frame: Baseline and Visit 2 (up to 1 month) and Baseline to Visit 3 (up to 2 years)

  2. Change in mean executive test composite score

    Change in the mean composite score of the following executive tests: phonemic (letter) fluency test, part B of the Trial Making Test, and the backwards trial of a Digit Span task, with higher composite score indicating better executive functioning

    Time frame: Baseline and Visit 2 (up to 1 month) and Baseline to Visit 3 (up to 2 years)

Secondary outcomes

  1. Change (in nanogram per liter; ng/L) in level of neurofilament light (NF-L)

    Change in a blood biomarker of neurodegeneration, with higher levels indicating greater neurodegeneration

    Time frame: Baseline to Visit 3 (up to 2 years)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study investigators are committed to resource sharing, according to NIH policy. At the conclusion of the study, after the final freeze to the database, a public use database will be created and made available along with specifications for its use. Johns Hopkins University will share anonymized genomic sequence data by depositing these data in the database of Genotypes and Phenotypes (dbGaP) (a controlled-access database funded by NIH). In addition, the investigators will share data from biosamples (saliva and blood samples), including genotype data, at the time of publication of the primary results or within 9 months of database lock, whichever comes first. These data will be shared via the Alzheimer's Clinical Trials Consortium (ACTC), and/or the National Alzheimer's Coordinating Center (NACC).

Supporting information: Study protocol

Time frame: At time of publication of primary results or within 9 months of database lock, whichever comes first. No end data for data availability has been determined at this time.

Access criteria: Researchers at academic institutions are eligible.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 60 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Apr 3, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2029
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05795634
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Mar 1, 2023
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Jan 29, 2026

Study contacts

Cynthia A Munro, PhD
Contact
cmunro@jhmi.edu
410-550-6271
Nicholas Bienko, MS
Contact
nbienko1@jhmi.edu
410-550-2036
Cynthia A Munro, PhD
principal investigator · Johns Hopkins School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion